We are live on ! Find out more
MTNB icon

Matinas BioPharma

34 hedge funds and large institutions have $8.24M invested in Matinas BioPharma in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

381% more capital inflows, than outflows

Capital inflows: $6.35M | Capital outflows: $1.32M

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

13% more funds holding

Funds holding: 30 → 34 (+4)

4.7% more ownership

Funds ownership: 7.58% → 12.28% (+4.7%)

Holders
34
Holders Change
+4
Holders Change %
+13.33%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
6
Reduced
1
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTNB Hedge Fund Activity: Q4 2018 in Review

34 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2018, worth a combined $8.24M — up 25% from $6.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MTNB positions and 10 closed out — a net gain of 4 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $4.43M. The largest seller was Goldman Sachs, exiting entirely with an estimated $261K sold.

  • 34 institutional investors held Matinas BioPharma (MTNB) as of Q4 2018, up from 30 in Q3 2018.
  • Funds reported $8.24M of Matinas BioPharma stock for Q4 2018, up 25% quarter-over-quarter.
  • 14 funds opened new Matinas BioPharma positions in Q4 2018 and 10 closed out, a net change of +4 holders.
  • The largest Matinas BioPharma buyer in Q4 2018 was Boxer Capital, an estimated $4.43M added.
  • The largest Matinas BioPharma seller in Q4 2018 was Goldman Sachs, an estimated $261K sold.

Based on aggregated 13F filings for Q4 2018.